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Introduction
Renal cell carcinoma (RCC) accounts for 2–3% of adult cancers
with over 30,000 new cases per year in the United States and an
associated 13,000 deaths [1]. Age-adjusted incidence rates of
16.2/100,000 in men and 8.0/100,000 in women have been
recorded during 1998–2002. In Europe, the highest incidence of
kidney cancer was observed in the Czech Republic, with rates of
approximately 22/100,000 in men and 11/100,000 in women. High
rates were also observed in the other eastern Europe countries
and in Germany, in contrast to most of the Asian and African pop-
ulations and some South American populations where rates up to
10–15 times lower are reported [2]. Thirty per cent of RCC
patients have metastatic disease at the time of diagnosis. An addi-
tional 20–30% with clinically localized disease at the time of
nephrectomy will subsequently develop metastatic disease. [1].
Metastatic RCC carries a dismal prognosis. Almost half of the
patients with RCC die within 5 years of diagnosis and 5-year sur-
vival rate for those with metastatic disease is less than 10% [3].
RCC is generally unresponsive to cytotoxic, hormonal and radia-
tion adjuvant therapies. Immunotherapies such as interleukin-2
and interferon- (IFN-) have been shown to be effective, albeit in
a minority of patients and often with severe drug-associated toxi-
city. Identification of tumour-specific target proteins and develop-
ment of potent anticancer compounds is, therefore, a high priority
in the treatment of advanced RCC.
Histone deacetylases (HDACs) represent one of the most
important intracellular molecules, as they modulate a wide vari-
ety of cellular functions. Abnormal histone acetylation status can
result in undesirable phenotypic changes, including develop-
mental disorders and cancer. Hence, HDAC inhibitors may be
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useful in cancer prevention, due to their ability to ‘reactivate’ the
expression of epigenetically silenced genes, including those
involved in differentiation, invasion and metastasis. Among the
growing list of HDAC-inhibitors, the branched-chain fatty acid
valproic acid (VPA) has been shown to possess distinct HDAC
inhibitory properties and to affect the growth and survival of
tumour cells in vitro and in vivo [4, 5]. VPA is an established
drug in the long-term therapy of epilepsy. It can be applied orally,
negative side effects are rare and it demonstrates expedient
pharmacokinetic properties.
VPA has been investigated in pre-clinical models of skin,
breast, colon, liver, prostate, cervix and small cell lung cancer.
Currently, the drug is in phase I trials [6, 7] for treatment of
solid tumours.
To assess whether VPA might be of benefit in treating RCC
patients, the potential of VPA to block growth properties of RCC
cell lines in vitro and in vivo were investigated and the underlying
mode of action explored. Also, VPA was combined with low-dosed
IFN- and the effects of the combination regimen compared to
single drug application. The experimental strategy was based on
earlier reports demonstrating that IFN- may enhance VPA’s
potency both in vivo and in vitro [8–10].
VPA could be shown to potently block RCC tumour cell pro-
liferation in vitro and prevent RCC tumour growth in vivo. VPA’s
activity is associated with reduction of HDAC and elevated
acetylation of histones H3 and H4. Entry of RCC tumour cells
into the S-phase of the cell cycle is delayed and the expression
pattern of cell cycle regulating proteins modified by VPA. It is of
particular interest that VPA–IFN- combination induced
stronger effects on RCC cell growth in vitro than VPA alone.
Still, VPA–IFN- combination and VPA monotherapy induced a
similar response in vivo. Based on these results, VPA provides
potent anti-tumour activity at multiple cellular levels and, there-
fore, may reveal significant therapeutic benefit in treating
advanced RCC. 
Materials and methods
Antibodies
Monoclonal antibodies were used, directed against proteins indicated sub-
sequently: Cell cycle: Cdk1/Cdc2 (IgG1, clone 1, dilution 1:2500), Cdk2
(IgG2a, clone 55, dilution 1:2500), Cdk4 (IgG1, clone 97, dilution 1:250),
Cyclin A (IgG1, clone 25, dilution 1:250), Cyclin B (IgG1, clone 18, dilution
1:1000), Cyclin D3 (IgG2b, clone 1, dilution 1:1000), Rb (IgG2a, clone 2,
dilution 1:250), Rb2 (IgG2a, clone 10, dilution 1:1000), p19 (IgG1, clone
52, dilution 1:5000), p21 (IgG1, clone 2G12, dilution 1:250), p27 (IgG1,
clone 57, dilution 1:500) were purchased from BD Biosciences
(Heidelberg, Germany). 
Apoptosis: Bax (IgG, polyclonal, dilution 1:200) and bcl-2 (IgG, poly-
clonal, dilution 1:200) were from Santa Cruz Biotechnology, Heidelberg,
Germany.
Histones: Anti-histone H3 (IgG, clone Y173, dilution 1:5000), anti-
acetylated H3 (IgG, clone Y28, dilution 1:500), anti-histone H4 (polyclonal
IgG, dilution 1:250), anti-acetylated H4 (Lys8, polyclonal IgG, dilution
1:500) and anti-HDAC3 (polyclonal IgG, dilution 1:2000) were all from
Biomol GmbH, Hamburg, Germany.
Anti--actin monoclonal antibody was obtained from Sigma
(Taufenkirchen, Germany).
Cell cultures
Kidney carcinoma Caki-1 and KTC-26 cells were purchased from LGC
Promochem (Wesel, Germany). A498 cells were derived from CLS
(Heidelberg, Germany). Tumour cells were grown and sub-cultured in
RPMI 1640 medium (Seromed, Berlin, Germany) supplemented with 10%
foetal calf serum, 100 IU/ml penicillin and 100 µg/ml streptomycin at 37C
in a humidified, 5% CO2 incubator. 
Drug treatment
Tumour cells were treated with VPA (gift from G. L. Pharma GmbH,
Lannach, Austria) at a final concentration of 0.25, 0.5 or 1 mM for 3 or 5
days (if not otherwise indicated). Controls remained untreated. In a further
experiment, tumour cells were incubated simultaneously with VPA and
IFN- (Roferon A; Roche Pharma AG, Grenzach-Wyhlen, Germany; 200
U/ml), and compared to cells treated with VPA or treated with IFN-, or
which remained untreated. 
Tumour cell growth
Cell proliferation was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) dye reduction assay (Roche
Diagnostics, Penzberg, Germany). Caki-1, KTC-26 or A498 cells (100 µl,
1  10
4 cells/ml) were seeded onto 96-well tissue culture plates and incu-
bated as described above. After 24 hrs, MTT (0.5 mg/ml) was added for an
additional 4 hrs. Thereafter, cells were lysed in a buffer containing 10% SDS
in 0.01 M HCl. The plates were allowed to stand overnight at 37C, 5% CO2.
Absorbance at 570 nm was determined for each well using a microplate
ELISA reader. Each experiment was done in triplicate. After subtracting
background absorbance, results were expressed as mean cell number.
Cell cycle analysis
Caki-1 cells were grown to 70% confluency and then treated with VPA or
with IFN- or with both VPA + IFN- (controls remained untreated).
Twenty-four hours before starting cell cycle analysis, Caki-1 were synchro-
nized at the G1–S boundary with aphidicolin (1 µg/ml). Caki-1 were resus-
pended in fresh (aphidicolin free) medium for 2 hrs, harvested, stained
with propidium iodide using a Cycle TEST PLUS DNA Reagent Kit (BD
Biosciences, Heidelberg, Germany), and then subjected to flow cytometry
with a FACScan flow cytometer (BD Biosciences). Ten thousand events
were collected from each sample. Data acquisition was carried out using
Cell-Quest software and cell cycle distribution calculated using the ModFit
software (BD Biosciences). The number of gated cells in G1, G2/M or 
S-phase was presented as percentage. 2378 © 2008 The Authors
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Western blotting
HDAC3, acetylated histones H3 and H4 were evaluated in Caki-1 tumour
cells by Western blot analysis. Cell cycle regulating proteins were also
explored in treated versus non-treated cell populations. Tumour cell
lysates were applied to a 7% polyacrylamide gel and electrophoresed
for 90 min. at 100 V. The protein was then transferred to nitrocellulose
membranes. After blocking with non-fat dry milk for 1 hr, the mem-
branes were incubated overnight with the respective antibodies and
dilutions listed above. HRP-conjugated goat-anti-mouse IgG (Upstate
Biotechnology, Lake Placid, NY, USA; dilution 1:5000) served as the
secondary antibody. The membranes were briefly incubated with ECL
detection reagent (ECL™, Amersham/GE Healthcare, München,
Germany) to visualize the proteins and exposed to an x-ray film
(Hyperfilm™ EC™, Amersham/GE Healthcare). -Actin (1:1000) served
as the internal control.
HDAC activity
For determining the inhibitory activity of VPA and/or IFN- for HDACs, a
cell-free assay (Color de Lys, Biomol) detecting HDAC1 and 2 was used
according to the manufacturer’s protocol. A nuclear extract of HeLa cells
containing HDAC1 and 2 was incubated for 10 min. at 37C with tricho-
statin A (TSA, 1µM final concentration) as a positive control of inhibition.
The HDAC reaction was initiated by adding a substrate of acetylated pep-
tides, incubated for 15–30 min., and followed by adding a colour devel-
oper. The absorbance of triplicate analyses was assayed at 405 nm with a
Bio-Tec microtitre-plate reader. For determining the HDAC activity of Caki-1
cells, the cell extracts (50 µg) that had been exposed to VPA, IFN-, to both
VPA + IFN-, or to control medium, were added to the substrate to deter-
mine the HDAC activity as described.
Tumour growth in vivo
For in vivo testing, 10
7 Caki-1 cells were injected subcutaneously to
male NMRI:nu/nu mice (EPO GmbH, Berlin, Germany). Treatment was
initiated when tumours had grown to a palpable size (5–6 mm diame-
ter). VPA was dissolved in 10% polyethylene glycol (PEG) 400/saline. It
was injected i.p. in doses of 200 mg/kg/day once daily (n = 8). A second
group received IFN- 5  10
5 IU/kg/day once daily (n = 8) and a third
group both VPA and IFN- (n = 8). The control group of mice was
treated with the solvent (n = 10). Tumour size was measured with cal-
lipers. Tumour volumes, relative tumour volumes (relative to the first
treatment day) and treated/control (T/C) values were calculated. Body
weight and mortality were recorded continuously to estimate tolerabil-
ity. Additionally, frozen tissue specimens were generated from nude
mice xenografts to evaluate cell cycle protein expression, bax, bcl-2, H3
and HDAC3 by Western blot analysis.
Statistics
All in vitro experiments were performed three to six times, in vivo experi-
ments were done eight to ten times. Statistical significance was investi-
gated by the Wilcoxon–Mann-Whitney U-test. Differences were considered
statistically significant at a P-value less than 0.05.
Results
Inhibition of RCC cell proliferation by VPA
Cell proliferation of Caki-1, KTC-26 and A498 cells was quanti-
fied 24 and 48 hrs after plating. To clearly interpret and compare
cellular growth characteristics, 24-hrs counts were all set at
100%. Growth pattern was similar in the untreated RCC cell
lines, cell counts of which all doubled after 24 hrs.
Simultaneous addition of VPA into the multiwell plates did not
influence cell growth (data not shown). However, a pre-incuba-
tion for 3 days with 0.25, 0.5 or 1 mM VPA dose dependently
and significantly blocked RCC cell proliferation. The anti-prolif-
erative effect of VPA was distinctly more pronounced when
tumour cells were pre-treated with the compound for 5 days,
whereby maximum growth reduction was achieved in the pres-
ence of 1 mM VPA (Fig. 1). 
Further studies concentrated on VPA dosages which induced
minimum (0.25 mM) or maximum (1 mM) effects. Because 
all RCC cell lines showed identical proliferation characteristics,
ongoing experiments were restricted to Caki-1 as the representa-
tive cell line. 
IFN- enhances the anti-proliferative 
activity of VPA
A total of 200 U/ml IFN- given alone for 3 days did not reduce
the growth capacity of Caki-1 cells, and 0.25 mM VPA (3-day
application) only slightly diminished cell proliferation. However,
when both compounds were combined, a significantly stronger
reduction of tumour cell growth was seen. In a similar fashion,
growth-blocking effects of 1 mM VPA became significantly
enhanced in the presence of IFN- (Fig. 2, left). The same phe-
nomenon was observed after a 5-day pre-incubation period. VPA
dose dependently (1 mM > 0.25 mM) reduced Caki-1 prolifera-
tion. The 5-day effects were more potent than the 3-day effects
and became even stronger when VPA was applied in combination
with IFN- (Fig. 2, right). 
VPA and VPA–IFN- combination increase 
histone H3 and H4 acetylation
Caki-1 cells were treated with VPA or VPA–IFN- combination for
12 and 24 hrs, and histone acetylation was assessed by Western
blotting. Caki-1 showed distinct reduction of HDAC3 and increase
of acetylated H3 and H4 under VPA treatment. Interestingly, VPA’s
effects were more prominent in presence of IFN-, although IFN-
alone did not modify histones. Determination of HDAC1 and 2 was
also done revealing strong inhibition under VPA, effect of which
became much more prominent in the additional presence of
IFN- (Fig. 3).J. Cell. Mol. Med. Vol 13, No 8B, 2009
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Fig. 1 Effects of VPA on kidney cancer proliferation in vitro. KTC-26, Caki-1 or A498 cells were treated with various concentrations of VPA for 3 or 5
days, or remained untreated (control). Cell proliferation was then assessed using the MTT dye reduction assay. Cell numbers at day 2 (48 hrs) were
compared to the number of day 1 (24 hrs, as 100%). One representative of six experiments is shown. 
*Indicates significant difference to controls. 
Fig. 2 Effects of VPA versus VPA–IFN- combination on kidney cancer proliferation in vitro. Caki-1 cells were treated with 0.25 mM or 1 mM VPA
alone or combined with IFN-. Incubation lasted for 3 or 5 days. Controls remained untreated. Cells were then counted after a further 24, 48 and 72
hrs using the MTT dye reduction assay. One representative of six experiments is shown. 
*Indicates significant difference to controls. 
#Indicates signif-
icant differences between VPA monotherapy and VPA–IFN- combination therapy.2380 © 2008 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
VPA and VPA–IFN- combination 
influences cell cycle regulation
VPA and the VPA–IFN- combination strongly blocked tumour cell
proliferation. Caki-1 cell lines were cultured with low- or high-
dosed VPA, with and without IFN-, and assayed for cell cycle
analysis. VPA significantly lowered the amount of tumour cells
entering the S-phase (1 mM VPA > 0.25 mM VPA). When com-
bined with IFN-, 0.25 mM VPA induced much stronger effects
than 0.25 mM VPA alone, independently of whether drug treat-
ment lasted for 3 or 5 days. This was also true when the experi-
mental protocol was based on the 1 mM VPA dosage given for
5 days, but not when Caki-1 were pre-treated for 3 days. IFN-
alone did not modify the cell cycle (Fig. 4). 
Alterations of cell cycle protein expression depended on the dos-
ing schedule. With respect to the 3-day pre-incubation, 0.25 mM
VPA enhanced p21 and p27 and slightly reduced CDK2 and CDK4.
One millimolar VPA strongly reduced CDK2 and cyclin B and strongly
elevated p21, Rb and cyclin D3.Effects of 1 mM VPA on CDK4 and
p27 were similar to the effects seen with 0.25 mM VPA. Combination
therapy was more effective than VPA monotherapy concerning the
expression of CDK2, CDK4, cyclin D3 (each 0.25 or 1 mM VPA–IFN-
versus 0.25 or 1 mM VPA), Rb and p21 (each 0.25 mM VPA–IFN-
versus 0.25 mM VPA). Interestingly, IFN- but not VPA induced  
up-regulation of CDK1 (Fig. 5). Similar effects were detected after a 
5-day pre-incubation period, except for cyclin B which was up-regu-
lated in the presence of 1 mM VPA or 1 mM VPA–IFN-, and p21,
which was reduced by VPA and VPA–IFN- (VPA–IFN- > VPA).
VPA treatment inhibits progression of 
tumour xenografts
Tumour xenografts were established in athymic nu/nu mice using
Caki-1 cells to evaluate the effects of VPA or VPA–IFN- combina-
tion on RCC cell growth in vivo. Compared to the untreated ani-
mals, application of VPA significantly diminished the tumour vol-
ume, with reduction of 70% at day 46, compared to the control
(Fig. 6). No body weight loss or diarrhoea was observed and all
animals (treated as well as non-treated) survived. Western blot
analysis revealed strong accumulation of p21 and bax in tissue
specimens of VPA-treated animals (Fig. 6, right). IFN- treatment
led to a moderate reduction of the tumour volume accompanied by
a reduction of CDK1 and bcl-2 and elevation of cyclin D3 and Rb. 
Fig. 3 Western blot analysis of HDAC3
expression and of H3 and H4 acetylation in
Caki-1, treated with 1 mM or 5 mM VPA or
with VPA–IFN- combination (A). Caki-1
were incubated with VPA/VPA–IFN- for 12
or 24 hrs. Cell lysates were then analysed
by specific antibodies as listed in ‘Materials
and methods’. -Actin served as the inter-
nal control. One representative experiment
of three is shown. n.d.= not done. For
determining the inhibitory activity of VPA or
VPA–IFN- combination on HDAC1 and 2,
the Color de Lys cell-free assay was used
(B). HDAC activity is given in µM deacety-
lated substrate/mg protein. 
*Indicates sig-
nificant difference to controls. 
#Indicates
significant differences between VPA
monotherapy and VPA–IFN- combination
therapy. One of three experiments is shown.
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Fig. 4 Cell cycle analysis of synchronized Caki-1 cells, treated with IFN-, with low- (0.25 mM) or high-dosed (1 mM) VPA or with VPA–IFN- combina-
tion. The phrase ‘3 days’ is related to a 3-day VPA incubation, the phrase ‘5 days’ is related to a 5-day VPA incubation. Controls remained untreated. The
cell population at each specific checkpoint is expressed as percentage of the total cells analysed. One representative experiment out of three is shown. 
Fig. 5 Western blot analyses of cell cycle
proteins, listed in ‘Materials and methods’.
Synchronized Caki-1 cells were treated with
IFN-, with low- (0.25 mM) or high-dosed
(1 mM) VPA, with VPA–IFN- combination
or remained untreated (control). The
phrase ‘3 days’ is related to a 3-day VPA
incubation, the phrase ‘5 days’ is related to
a 5-day VPA incubation. Cell lysates were
subjected to SDS-PAGE and blotted on the
membrane incubated with the respective
monoclonal antibodies. -Actin served as
the internal control. The figure shows 
one representative from three separate
experiments. 2382 © 2008 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Surprisingly, VPA–IFN- combination treatment was not supe-
rior to VPA monotherapy. Western blot data indicated cooperative
processes with respect to CDK1 and CDK4 down-modulation and
HDAC3 was nearly lost by the combined use of VPA and IFN-. On
the other hand, combination regimen reverted the strong p21 and
bcl-2 accumulation caused by VPA alone. 
Discussion
HDAC are critically important in regulating gene and protein
expression and offer a target for therapeutic intervention. The
results presented here provide evidence that the HDAC inhibitor
VPA potently blocks RCC cell growth both in vitro and in vivo. No
experiments have been carried out so far dealing with this issue.
However, VPA has recently been shown to inhibit hypoxia-
inducible factor 1  in RCC cells which plays a critical role in tran-
scriptional gene activation involved in tumour angiogenesis [11].
VPA administered for 5 days was more potent than a 3-day
application. Prolonged VPA exposure has been shown to be nec-
essary to modify neuroectodermal tumour cells [12, 13], and Xia
et al. has suggested that chronic administration of VPA is required
to achieve therapeutic benefits with prostate carcinoma [14]. In
the RCC xenograft model significant tumour reduction was not
seen until 10 days after starting chronic VPA application. It seems
therefore, that long-term application of VPA is necessary to delay
tumour cell growth. 
VPA decreased the proportion of cells in the S-phase and
increased the proportion of cells in the G0-/G1-phase of the cell
cycle. Simultaneously, the expression pattern of cell cycle regulat-
ing proteins became modified. In particular, cyclin D3, p27 and Rb
were up-regulated by VPA. The up-regulation was not dependent
on the exposure time.
Data indicate that p27 is involved in cell-cycle control, and the
loss of p27 expression is a risk factor for disease recurrence and
the strongest predictor of cancer-specific survival [15, 16]. VPA
may, therefore, interfere with the mitotic cycle of RCC tumour cells
by enhancing the p27 expression level. The role of cyclin D3 in
tumour progression is discussed controversially. Based on an
immunohistochemical study, high cyclin D3 expression has been
associated with high proliferation in RCC, although this was
related to only 16% of the tumours [17, 18]. In another study,
cyclin D3 levels were significantly higher in ovarian tumours of
low malignant potential than in ovarian adenocarcinomas, and
absent cyclin D3 expression was an indicator of poor survival in
the patient cohort [19]. Suppressive activity of cyclin D3 has also
been reported in skin carcinogenesis [20], in pancreatic adenocar-
cinomas [21] and prostate carcinoma [22]. In good accordance
with our data, exposure of C6 glioma cells to VPA induced a
marked up-regulation of cyclin D3 and decreased expression of
the proliferating cell nuclear antigen, both of which are detectable
in the G1-phase [23].
Evidence has been provided that cyclin D3 expression posi-
tively correlates with Rb protein expression [19]. In fact,
hypophosphorylated Rb is strongly involved in the repression of
proliferation-associated genes [24]. Although Rb expression has
not been analysed in an RCC cell culture model, aberrant Rb lev-
els were detected in tissue specimens taken from RCC patients
[18]. Recently, the short-chain fatty acid HDAC inhibitors tribu-
tyrin and sodium butyrate were demonstrated to enhance expres-
sion levels of hypophosphorylated Rb in prostate cancer [25], and
VPA was shown to induce G1 arrest in association with Rb up-reg-
ulation in human melanoma cells [26]. We, therefore, postulate
that VPA’s effects on RCC cell mitosis may also be caused by mod-
ified Rb and cyclin D3 protein levels. 
Although cyclin D3, p27 and Rb elevation seem to be a general
feature of VPA’s mode of action, modifications of further cell sig-
nalling proteins are difficult to interpret. Notably, cyclin B was
down-regulated after 3 days, but up-regulated after a 5-day VPA
exposure. The p21 was enhanced after 3 days, but lowered after 5
days by VPA. Interestingly, control values were also modified time
Fig. 6 Effect of VPA and VPA–IFN- combi-
nation on RCC xenografts. Caki-1 xenografts
were established in male athymic mice.
Animals in the treatment arm received 200
mg/kg VPA or IFN-5 10
5IU/kg once daily
(n = 8), and a third group received both VPA
and IFN- (n = 8). The control group of mice
was treated with the solvent (n = 10).
*Indicates significant difference to the con-
trol animals. Western blot analysis of cell
cycle regulating proteins, bax, bcl-2, H3 and
HDAC3 was carried out on the tissue
  specimens using specific antibodies as
listed in ‘Materials and methods’ (fig 6,
right). -Actin served as the internal control.
Western blot data from one of three repre-
sentative experiments are shown. 
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dependently, cyclin B being diminished, p21 enhanced after 5
days, compared to the 3-day values. Possibly, periodic alterations
of p21 and cyclin B levels take place, which may account for the
persistent proliferation of cancer cells [27]. If this is the case, the
effects of VPA might be due to its dampening this oscillatory
behaviour, returning the cells to normal dissipative dynamics.
However, this concept is purely speculative. The existence of
cyclin B double bands may also be interpreted in this way: There
is no difference between control and the various therapies in the
3-day experiment but a loss of the lower band for 1 mM VPA (with
or without IFN-). In case of the 5-day experiment, the lower
(bona fide unspecific) band is unaltered and the (bona fide spe-
cific) cyclin B band increases from control through increasing VPA
concentrations and addition of IFN-.
A total of 200 mg/kg bw VPA significantly reduced the growth
of xenografted RCC cells which clearly confirmed our in vitro data.
The effect was concomitant with altered expression of proteins
related to the malignant phenotype, including a massive increase
of p21 and bax. Interestingly, the same dosing schedule has been
recommended by others to diminish prostate cancer xenografts
[28], and to suppress tumour angiogenesis in vivo [29]. However,
a different VPA regimen may be required to treat other tumour
types. Daily i.p. injections of 366 mg/kg VPA were necessary to
inhibit gastrointestinal tumour growth in nu/nu mice [30], and
neuroblastoma xenograft studies were based on 400 mg/kg VPA
[8, 31]. The present data are related to RCC, and it may be possi-
ble that different tumour types require different VPA regimens. 
Finally, whether IFN- added to VPA in low concentrations could
offer an advantage over VPA monotherapy was investigated. It has
recently been shown that IFN-, when used together with VPA, sig-
nificantly potentiates the anti-tumoural activity of VPA on the human
N-myc amplified cell line BE(2)-C, whereas IFN- on its own has lit-
tle or no effect [9]. Most strikingly, VPA plus IFN- synergistically
inhibited growth of UKF-NB-3 xenograft tumours in nude mice and
induced complete cures in two out of six animals, whereas single
treatment merely inhibited tumour growth [8]. Furthermore, IFN-
has been documented to enhance the anti-angiogenic action of
HDAC-inhibitors in neuroblastoma bearing transgenic mice [10],
and to potentiate the influence of HDAC-inhibitors on growth and
invasion of lung and liver cancer cells [32, 33].
A combination VPA–IFN- regimen was more effective than a
VPA monotherapy. IFN- alone did not act on RCC proliferation,
showing that IFN- boosts VPA’s anti-tumoural properties. The
same was true with respect to several cell cycle regulating pro-
teins, particularly CDK2, CDK4, cyclin B, Rb, and (partially) p21. 
Nevertheless, IFN- was also found to counteract some effects
of VPA. Notably, p21 which was strongly up-regulated by 1 mM
VPA after 3 days was reduced by the VPA–IFN- combination. In a
similar fashion, cyclin D3 was altered more distinctly by 1 mM VPA
alone than by the VPA–IFN- combination therapy. Kuljaca and
coworkers observed a similar phenomenon. Although combination
therapy with IFN- and the HDAC inhibitor TSA exerted a synergis-
tic action on prostate and breast cancer cell growth, p21 elevation
was much more pronounced by TSA alone than by the TSA–IFN-
combination [10]. The authors concluded that slight inhibition of
p21 sensitizes p21-expressing cancer cells to the combination
therapy. However, it is not clear if this may also hold true for the
RCC model or if the discrepancies are irrelevant side effects. 
Surprisingly, the in vitro data were not confirmed by the in vivo
model, because the VPA–IFN- combination was not superior to
VPA monotherapy. However, when interpreting the data, we
should be aware that different experimental protocols have been
used. VPA and IFN- were administered once in the in vitro sys-
tem whereas animals were treated chronically over a prolonged
time period. Therefore, drug concentrations reaching the target
cells may vary in vitro and in vivo and, consequently, different
tumour responses may be evoked. Based on a human breast can-
cer cell line, the concomitant presence of the HDAC inhibitor
sodium butyrate and IFN- significantly improved the antiprolifer-
ative effect of IFN- alone, however sequential treatment sodium
butyrate-IFN- did not enhance the inhibitory activity seen with
either drug alone [34]. This issue should be considered, because
nude mice were treated first with VPA and afterwards with IFN-,
whereas RCC cell cultures were incubated with VPA and IFN-
simultaneously. Further reports suggest that IFN- enhances the
anti-tumoural potential of VPA when applied in sub-therapeutic
concentrations,  i.e. when IFN- alone exerts no anti-cancer
effects [35, 36]. 
This (still hypothetical) assumption might explain the discrep-
ancy between the in vitro and in vivo results. Indeed, synergistic
combinational anti-cancer effects became evident when IFN-
alone exerted no biological activity on RCC cells, i.e. in vitro but
not in vivo. The molecular background of VPA–IFN- interactions
in vivo has not been evaluated in detail. However, though a syn-
ergy was seen with respect to CDK1, CDK4 and HDAC3 expres-
sion, VPA–IFN- combination strongly counteracted the effects of
VPA on bcl-2 and, most impressively, on p21 expression.
Presumably, counter-regulation of p21 and bcl-2 was (at least in
part) responsible for the loss of synergism in treated animals.
Ongoing studies dealing with this issue are underway. 
In summary, administration of VPA resulted in a marked
decrease in proliferation of RCC cells in vitro and significant
reduction in tumour volume in vivo. We postulate that VPA’s
effects are based on the induction of cell cycle arrest and alter-
ations of cell cycle regulating proteins. Still, the protein data are
somewhat descriptive and, therefore, experiments using trans-
fected RCC cells to knock down a particular protein may further
deepen our knowledge about VPA’s mode of action. Because VPA
has been approved by the U.S. Food and Drug Administration,
with an established safety profile, and because drug concentra-
tions used in the present study are within the therapeutic range, it
can be considered an attractive candidate for clinical trials.
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